Suppr超能文献

淋病奈瑟菌感染过程中抗溶菌酶策略所需的表面展示脂蛋白 Sl iC。

SliC is a surface-displayed lipoprotein that is required for the anti-lysozyme strategy during Neisseria gonorrhoeae infection.

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon, United States of America.

Department of Microbiology and Immunology, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.

出版信息

PLoS Pathog. 2018 Jul 5;14(7):e1007081. doi: 10.1371/journal.ppat.1007081. eCollection 2018 Jul.

Abstract

Lysozymes are nearly omnipresent as the first line of immune defense against microbes in animals. They exert bactericidal action through antimicrobial peptide activity and peptidoglycan hydrolysis. Gram-negative bacteria developed several weapons to battle lysozymes, including inhibitors of c-type lysozymes in the MliC/PliC family and the Neisseria adhesin complex protein (ACP). Until the recent discovery of ACP, no proteinaceous lysozyme inhibitors were reported for the genus Neisseria, including the important human pathogen N. gonorrhoeae. Here, we describe a previously unrecognized gonococcal virulence mechanism involving a protein encoded by the open reading frame ngo1063 that acts to counteract c-type Iysozyme and provides a competitive advantage in the murine model of gonorrhea. We named this protein SliC as a surface-exposed lysozyme inhibitor of c-type lysozyme. SliC displays low overall primary sequence similarity to the MliC/PliC inhibitors, but we demonstrate that it has a parallel inhibitory mechanism. Our studies provide the first evidence that bacterial proteinaceous lysozyme inhibitors protect against host lysozyme during infection based on lack of attenuation of the ΔsliC mutant in lysozyme knock-out mice, and that the conserved residues involved in lysozyme inhibition, S83 and K103, are functionally indispensable during infection in wild type mice. Recombinant SliC completely abrogated the lytic activity of human and chicken c-type lysozymes, showing a preference towards human lysozyme with an IC50 of 1.85 μM and calculated KD value of 9.2 ± 1.9 μM. In contrast, mutated SliC bearing S83A and K103A substitutions failed to protect fluorescein-labeled cell-wall from lysozyme-mediated hydrolysis. Further, we present data revealing that SliC is a surface-displayed lipoprotein released in membrane vesicles that is expressed throughout all phases of growth, in conditions relevant to different niches of the human host, and during experimental infection of the murine genital tract. SliC is also highly conserved and expressed by diverse gonococcal isolates as well as N. meningitidis, N. lactamica, and N. weaveri. This study is the first to highlight the importance of an anti-lysozyme strategy to escape the innate immune response during N. gonorrhoeae infection.

摘要

溶菌酶几乎无处不在,是动物抵御微生物的第一道免疫防线。它们通过抗菌肽活性和肽聚糖水解发挥杀菌作用。革兰氏阴性菌开发了几种武器来对抗溶菌酶,包括 MliC/PliC 家族的 c 型溶菌酶抑制剂和奈瑟菌黏附复合物蛋白(ACP)。直到最近发现 ACP,才报道了奈瑟菌属中没有蛋白溶菌酶抑制剂,包括重要的人类病原体淋病奈瑟菌。在这里,我们描述了一个以前未被认识到的淋病奈瑟菌毒力机制,涉及开放阅读框 ngo1063 编码的一种蛋白,该蛋白可对抗 c 型溶菌酶,并在淋病的小鼠模型中提供竞争优势。我们将这种蛋白命名为 SliC,即 c 型溶菌酶的表面暴露溶菌酶抑制剂。SliC 与 MliC/PliC 抑制剂的整体一级序列相似性较低,但我们证明它具有平行的抑制机制。我们的研究首次提供了证据,表明细菌蛋白溶菌酶抑制剂可在感染过程中保护宿主溶菌酶免受侵害,因为缺乏 SliC 突变体在溶菌酶敲除小鼠中的衰减,并且参与溶菌酶抑制的保守残基 S83 和 K103 在野生型小鼠感染过程中是功能不可或缺的。重组 SliC 完全消除了人源和鸡源 c 型溶菌酶的裂解活性,对人源溶菌酶表现出偏好,IC50 为 1.85 μM,计算出的 KD 值为 9.2 ± 1.9 μM。相比之下,带有 S83A 和 K103A 取代的突变 SliC 无法保护荧光标记的细胞壁免受溶菌酶介导的水解。此外,我们提供的数据表明 SliC 是一种表面展示的脂蛋白,可在膜泡中释放,在与宿主不同生态位相关的所有生长阶段、条件下以及实验性感染小鼠生殖道时表达。SliC 也高度保守,由多种淋病奈瑟菌分离株以及脑膜炎奈瑟菌、奈瑟菌 lactamica 和奈瑟菌 weaveri 表达。这项研究首次强调了在淋病奈瑟菌感染过程中,一种抗溶菌酶策略对于逃避先天免疫反应的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e717/6033465/1eedac6c771d/ppat.1007081.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验